2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Bevacizumab

Bevacizumab  (Synonyms: Anti-Human VEGF, Humanized Antibody)

Cat. No.: HY-P9906 Purity: 98.30%
SDS COA

Molarity Calculator

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

For research use only. We do not sell to patients.

CAS No. : 216974-75-3

Size Price Stock Quantity
1 mg USD 160 In-stock
5 mg USD 490 In-stock
10 mg USD 740 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Bevacizumab:

Bevacizumab Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
IC50 & Target

VEGF[1]
In Vitro

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bevacizumab Related Antibodies
In Vivo

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

149 kDa(Average)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bevacizumab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.
Purity & Documentation

Purity: ≥99.0%

SDS (251 KB)

COA (291 KB)

Inhibitory Antibodies User Guide (602 KB)
References
Cell Assay
[2]

Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2][3]

Rats[2]
After modeling, ninety rats are randomly divided into five groups (eighteen rats per group) and receive a subconjunctival injection with 0.05 mL per rat of (1) 0.9% NaCl, (2) solvent, (3) 25 mg/mL Bevacizumab and (4) 25 mg/mL FD006 in the superior temporal conjunctiva on the day after modeling. All chemical burns and treatments are performed by one investigator. The operator is blinded to the treatment group from which each cornea is derived. At postoperative days 3, 7, 14, 21 and 28, the eyes are harvested for further studies after the rats are sacrificed.
Mice[3]
Five-week-old Balb/cAnNCrlBR athymic (nu+/nu+) mice are injected into the fourth mammary fat pad with MDA-MB-468 cells (107 cells per mice) resuspended in 200 μL of Matrigel. Seven days after the tumor cell injection, tumor-bearing mice are randomly assigned (n=10 per group) to receive the following: NVP-LDE225 20 mg/kg per os every day for 4 weeks; Bevacizumab 5 mg/kg intravenously (i.v.), twice a week for 4 weeks. Tumor diameter is assessed with a vernier caliper, and tumor volume (cm3) is measured.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bevacizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bevacizumab216974-75-3Anti-Human VEGF, Humanized AntibodyVEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bevacizumab
Cat. No.:
HY-P9906
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.